ArticlePLoS computational biology2025
Utargetome: A targetome prediction tool for modified U1-snRNAs to identify distal-target positions with improved selectivity.
Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The endogenous U1 small nuclear RNA (U1-snRNA) plays a crucial role in splicing initiation through base-pairing to donor splice sites (5'-SSs). Likewise, modified U1s that carry a mutation-adapted 5'-terminal sequence have been demonstrated to rescue exon splicing when this is disrupted by genetic mutations within the 5'-SS. Given the base-pairing flexibility of the endogenous U1, the selectivity of modified U1s requires investigation. We developed a computational pipeline (Utargetome) that considers combinations of mismatches and alternative annealing registers to predict the transcriptome-wide binding sites (or targetome) of a U1. The pipeline accuracy was tested by recapitulating well-established alternative annealing registers and specificity for 5'-SSs in the predicted targetome of the human endogenous U1. It was then applied to analyse the targetome of 54 modified U1s that have been demonstrated to restore exon inclusion when affected by 5'-SS pathogenic mutations. While the targetome size was found to be wide-ranging, the off-target load appeared to be reduced for U1s targeting distal sites from the canonical U1-binding position. This feature was predicted also for a large set of 30,204 newly designed U1s targeting 839 5'-SS pathogenic mutations that were expected to affect exon inclusion. Targetome analysis indeed revealed an optimal distal-targeting position at 3 nucleotides downstream from the canonical 5'-SS, for which a modified U1 is likely to have minimal off-targets at 5'-SSs and acceptor splice sites (3'-SSs). Based on these insights, we propose to implement targetome prediction in the design and optimization of therapeutic U1s with improved selectivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.